Stay updated with breaking news from Treatment Patterns. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
First presentation of results from primary analysis of Phase 2 TRANSCEND FL study evaluating second-line treatment with Breyanzi® in relapsed or refractory follicular lymphoma demonstrate its...
/PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKTQ), a global specialty pharmaceutical company, recently shared findings from Mallinckrodt's latest health...
The real-world evidence study examined patients with PsA taking secukinumab and ixekizumab, highlighting 80% treatment persistence after 1 year.
Incyte (NASDAQ:INCY) today announced multiple abstracts featuring new data from across its dermatology portfolio have been accepted for presentation at the upcoming European Academy of Dermatology and Venereology (EADV)
Incyte today announced multiple abstracts featuring new data from across its dermatology portfolio have been accepted for presentation at the upcoming European Academy of Dermatology and Venereology...